Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Ankylosing Spondylitis: Randomized Placebo-Controlled Phase III Trial
2012-000046-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in ankylosing spondylitis (AS) and Spondylopathy (3 arms), sponsored by Novartis. Primary endpoint: ASAS 20 response at Week 16. Started Jul 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)Spondylopathy
Beyond the preview
Go deeper on 2012-000046-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000046-35.